So far, Several reports concluded that CD200 expression is also associated with the progression of various solid cancers, such as bladder cancer, lung cancer, breast cancer prostate carcinoma, cutaneous squamous cell carcinoma and acute myeloid leukemia (Kretz-Rommel et al., 2007; Lawlor et al., 2019; Aref et al 2020). Here, CD200 is linked to lung carcinoma.